Ongoing Research of Immunotherapy in HNSCC – OncLive
OncLive |
Ongoing Research of Immunotherapy in HNSCC
OncLive Ezra Cohen, MD: Without a doubt, immunotherapy has changed the landscape for patients with squamous cell carcinoma of the head and neck. We've seen approval of both nivolumab and pembrolizumab for patients with recurrent and metastatic disease. |
